Press release
CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CTX-009 was well tolerated and demonstrated single agent activity in heavily pre-treated patients with solid tumor who are resistant to anti-VEGF therapies,
About this update from Compass Therapeutics, Inc.
[{"type":"text","content":"\n\nCTX-009 was well tolerated and demonstrated single agent activity in heavily pre-treated patients with solid tumor who are resistant to anti-VEGF therapies, mostly of colorectal and gastric origins\n\n\nThe structural differences between CTX-009 and other bispecifics targeting these pathways, as well as the affinities and avidities to their targets, may be the drivers for the differentiated safety and efficacy data observed\n\n\nThe maximum tolerated dose (MTD) was not reached, and the recommended Phase 2 doses (RP2D) of CTX-009 were determined to be 10.0 and 12.5 mg/kg biweekly\n\n\nOverall response rate (ORR) of CTX-009 as a monotherapy across all doses tested (0.3 - 17.5 mg/kg) was 8% and the disease control rate (DCR) was 62% in patients treated at the 3rd and 4th line settings\n\n\nTreatment with CTX-009 at the RP2D (10.0 mg/kg and 12.5 mg/kg) led to 19% (n=3/16) ORR, not including an additional unconfirmed partial response, and a 69% DCR (n=11/16)\n\n\nA Phase 1b study of CTX-009 in combination with chemotherapy and a Phase 2 study are underway\n\n\n BOSTON & SEONGNAM, S. Korea & SHANGHAI/SUZHOU, China--(BUSINESS WIRE)--\nCompass Therapeutics, Inc. (OTC:CMPX) and ABL Bio (KOSDAQ: 298380) presented today clinical trial data for CTX-009 (ABL001/ES104), a dual anti-angiogenic bispecific antibody targeting DLL4 and VEGF-A, at an oral plenary session during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Abstract Number: 4749; Session Title: Plenary Session 2: New Drugs on the Horizon I).\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211008005422/en/\nThe first in human Phase 1 single agent dose escalation and expansion study evaluated CTX-009 across nine dose levels. The study enrolled 45 heavily pre-treated patients with cancers primarily of colorectal and gastric origin. CTX-009 was well tolerated across all doses evaluated, with no dose-limiting toxicities reported. The most frequent treatment related adverse event was hypertension, observed in 17 patients of the 45 patients enrolled. Among those, 7 patients reported Grade 3 hypertension and the rest had Grade 1 or Grade 2 (16%). Only 4 mild cases of pulmonary hypertension were reported that were all reversible, and CTX-009 demonstrated significant clinical activity...